We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

51 hedge funds and large institutions have $99.2M invested in OnKure Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital invested

Capital invested by funds: $49M → $99.2M (+$50.2M)

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

84.96% more ownership

Funds ownership: 8.63% → 93.59% (+85%)

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0% more funds holding

Funds holding: 51 → 51 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
51
Holders Change
–
Holders Change %
0%
% of All Funds
0.67%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
20
Increased
20
Reduced
10
Closed
19
Calls
$243K
Puts
–
Net Calls
+$243K
Net Calls Change
+$140K

Top Buyers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
+$27.8M
2
Citadel Advisors
Citadel Advisors
Florida
+$16.1M
3
PA
Perceptive Advisors
New York
+$15.2M
4
SB
Samsara BioCapital
California
+$12.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$9.36M

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$5.88M
2
OCA
Octagon Capital Advisors
New York
-$3.83M
3
AI
Acuitas Investments
Washington
-$685K
4
Two Sigma Investments
Two Sigma Investments
New York
-$230K
5
JC
JBF Capital
Colorado
-$136K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$408K -$40.9K -2,703 -5%
AC
27
Aldebaran Capital
Indiana
$392K +$5.45K +360 +0.8%
6CM
28
683 Capital Management
New York
$373K +$657K +43,371 New
CF
29
Cantor Fitzgerald
New York
$294K +$540K +35,700 New
CSS
30
Cubist Systematic Strategies
Connecticut
$177K +$310K +20,496 +38,672%
Northern Trust
31
Northern Trust
Illinois
$165K +$224K +14,776 +336%
XT
32
XTX Topco
Cayman Islands
$160K +$282K +18,633 New
SC
33
Shay Capital
New York
$129K +$184K +12,154 +425%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$122K -$127K -8,402 -37%
Walleye Capital
35
Walleye Capital
New York
$116K +$204K +13,495 New
OAC
36
OMERS Administration Corp
Ontario, Canada
$104K +$183K +12,100 New
Barclays
37
Barclays
United Kingdom
$75.2K +$132K +8,718 +37,904%
CUAMC
38
China Universal Asset Management Company
China
$23.1K +$30.9K +2,040 +317%
UBS Group
39
UBS Group
Switzerland
$19K +$31.7K +2,094 +1,760%
TRCT
40
Tower Research Capital (TRC)
New York
$18.9K +$2.57K +170 +8%
Wells Fargo
41
Wells Fargo
California
$13.9K +$22.7K +1,500 +1,250%
Morgan Stanley
42
Morgan Stanley
New York
$8.02K -$83.6K -5,520 -86%
Mirae Asset Global Investments
43
Mirae Asset Global Investments
South Korea
$3.44K +$4.56K +301 +249%
JP Morgan Chase
44
JP Morgan Chase
New York
$2.9K -$6.51K -430 -56%
Group One Trading
45
Group One Trading
Illinois
$2.48K +$3.62K +239 +478%
GFM
46
GF Fund Management
China
$2.29K +$4.03K +266 New
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$2.03K +$3.57K +236 New
Osaic Holdings
48
Osaic Holdings
Arizona
$1.31K -$15 -1 -0.7%
Citigroup
49
Citigroup
New York
$877 -$3.83K -253 -71%
MCM
50
MAI Capital Management
Ohio
$52 +$91 +6 New
1
2
3

OKUR Hedge Fund Activity: Q4 2024 in Review

51 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q4 2024, worth a combined $99.2M — up 103% from $49M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new OKUR positions and 19 closed out — a net gain of 1 holder — while 20 added to existing stakes and 10 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $27.8M. The largest seller was BML Capital Management, exiting entirely with an estimated $5.88M sold.

  • 51 institutional investors held OnKure Therapeutics (OKUR) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $99.2M of OnKure Therapeutics stock for Q4 2024, up 103% quarter-over-quarter.
  • 20 funds opened new OnKure Therapeutics positions in Q4 2024 and 19 closed out, a net change of +1 holder.
  • The largest OnKure Therapeutics buyer in Q4 2024 was Cormorant Asset Management, an estimated $27.8M added.
  • The largest OnKure Therapeutics seller in Q4 2024 was BML Capital Management, an estimated $5.88M sold.

Based on aggregated 13F filings for Q4 2024.